Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically accepted treatment to cure or halt its progression. The Food and Drug Administration has …
D De Boer, N Nguyen, J Mao, J Moore, EJ Sorin - Biomolecules, 2021 - mdpi.com
The present article reviews published efforts to study acetylcholinesterase and butyrylcholinesterase structure and function using computer-based modeling and simulation …
Quinazolines are considered as a promising class of bioactive heterocyclic compounds with broad properties. Particularly, the quinazoline scaffold has an impressive role in the design …
T Mohamed, PPN Rao - European journal of medicinal chemistry, 2017 - Elsevier
A library of fifty-seven 2, 4-disubstituted quinazoline derivatives were designed, synthesized and evaluated as a novel class of multi-targeting agents to treat Alzheimer's disease (AD) …
V Kumar, A Saha, K Roy - Computational Biology and Chemistry, 2020 - Elsevier
In this research, we have implemented two-dimensional quantitative structure-activity relationship (2D-QSAR) modeling using two different datasets, namely, acetylcholinesterase …
G Le-Nhat-Thuy, NN Thi, H Pham-The, TAD Thi… - Bioorganic & Medicinal …, 2020 - Elsevier
A library of twelve quinazoline-triazole hybrid compounds were designed, synthesized and evaluated as a novel class of acetylcholinesterase inhibitors to treat Alzheimer's disease …
In search of potent inhibitors of cholinesterases, we have synthesized and evaluate a number of 2, 3-dihydroquinazolin-4 (1H)-one derivatives. The synthetic approach provided …
Alzheimer is a prolonged neurodegenerative disease which degenerate the brain cells and particularly affects the person ability to function independently. Despite of dynamic research …
M Hatami, Z Basri, BK Sakhvidi, M Mortazavi - International …, 2023 - Elsevier
The design and development of effective multitargeted agents in treating Alzheimer disease (AD) has always been a hot topic in the field of drug discovery. Since AD is a multifactorial …